AMRI to present obesity compound Phase I clinical results

MCH 1 clinical results to be presented at European Congress on Obesity

AMRI will present results from a Phase 1 clinical study with its Melanin Concentrating Hormone Receptor 1 ( MCH 1 ) antagonist, ALB-127158(a), at the 18th European Congress on Obesity (ECO2011), which is taking place from 25 – 28 May 2011 in Istanbul, Turkey.

The results will be presented by Dr Nicholas Moore, director of development and pharmacology, as a Hot Topic Poster (poster HTP.022) during the afternoon session on Thursday, 26 May, 2011 and in a subsequent oral session on Friday, 27 May 27 2011 at 5:45 p.m.

The presentation will provide data from both a single ascending dose study and a multiple ascending dose study designed to assess safety, tolerability and pharmacokinetics. The multiple ascending dose study included evaluations designed to indicate pharmacodynamic effects of the compound.

The clinical study was initiated in July 2010 following promising preclinical results that showed high levels of MCH 1 receptor occupancy leading to a sustained, dose-related reduction in food intake in dietary-induced obese mice.

‘We are pleased to be sharing our Phase I results for this promising new compound,’ said Dr Bruce Sargent, senior vice president of drug discovery. ‘MCH 1 receptor antagonism has been long recognised as a potential approach to treatment of obesity. We are proud to be one of the first companies to progress a compound through Phase I clinical trial.’

Companies